Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ensartinib + Fruquintinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ensartinib | X-396 | ALK Inhibitor 32 | Ensartinib (X-396) is a small molecule inhibitor of ALK, which inhibits downstream signaling and potentially leads to decreased growth of ALK-expressing tumors (PMID: 21613408, PMID: 31628085). | |
Fruquintinib | Fruzaqla | HMPL-013 | VEGFR Inhibitor (Pan) 36 | Fruzaqla (fruquintinib) binds and inhibits VEGFR1/2/3, potentially resulting in reduced cell proliferation and decreased tumor growth (PMID: 25482937, PMID: 31790382). Fruzaqla (fruquintinib) is FDA approved for use in patients with metastatic colorectal cancer who have received prior therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|